Skip to main content
High RiskFDAfda-Z-1370-2023OTHER

Titan Touch Scro Zero Ang 20cm, Catalog Number ES29202400; inflatable penile Prosthesis

Units Affected
20
Recall Date
March 1, 2023
Issuing Agency
Hazard
Other

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-1370-2023.

A decrease in wall thickness has the potential for a premature pump failure, compared to a pump with standard wall thickness, based on the number of interactions with the pump to inflate and deflate the penile prosthesis.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-1370-2023.

Recall ongoing. Follow firm instructions.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Coloplast Manufacturing Us, Llc or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-Z-1370-2023.

Coloplast Manufacturing US, LLC

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Coloplast Manufacturing Us, Llc Recall FAQ

Coloplast Manufacturing Us, Llc is the subject of a medical implants safety report: Titan Touch Scro Zero Ang 20cm, Catalog Number ES29202400; inflatable penile Prosthesis. The notice was published on March 1, 2023 by the U.S. Food and Drug Administration (FDA). Approximately 20 units are potentially affected.